BMEA Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Biomea Fusion, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.65 |
52 Week High | US$22.74 |
52 Week Low | US$3.61 |
Beta | -0.45 |
11 Month Change | 34.84% |
3 Month Change | 113.37% |
1 Year Change | 7.57% |
33 Year Change | 6.01% |
5 Year Change | n/a |
Change since IPO | -37.37% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Sep 30We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
Jun 10We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth
Feb 22Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?
Nov 07We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
Jul 12Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
Mar 29We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely
Nov 03Biomea Fusion GAAP EPS of -$0.59 beats by $0.01
Aug 01We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Jul 20Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans
Mar 16Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
Nov 27Biomea Fusion: Patience Warranted
Sep 23Shareholder Returns
BMEA | US Biotechs | US Market | |
---|---|---|---|
7D | 8.1% | 0.6% | 0.8% |
1Y | 7.6% | 27.4% | 38.4% |
Return vs Industry: BMEA underperformed the US Biotechs industry which returned 27.4% over the past year.
Return vs Market: BMEA underperformed the US Market which returned 38.4% over the past year.
Price Volatility
BMEA volatility | |
---|---|
BMEA Average Weekly Movement | 9.8% |
Biotechs Industry Average Movement | 9.8% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BMEA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BMEA's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 112 | Thomas Butler | biomeafusion.com |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc. Fundamentals Summary
BMEA fundamental statistics | |
---|---|
Market cap | US$421.85m |
Earnings (TTM) | -US$139.65m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.0x
P/E RatioIs BMEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BMEA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$139.65m |
Earnings | -US$139.65m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.86 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did BMEA perform over the long term?
See historical performance and comparison